常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.45/0.06
|
|
企业价值
112.95M
|
| 资产负债 |
|
每股账面净值
0.97
|
| 现金流量 |
|
现金流量率
0.25
|
| 损益表 |
|
收益
124.96M
|
|
每股收益
1.75
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/07 20:43 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild tomoderate pain. |

0.7605 
